Zykadia for Metastatic Non-Small Cell Lung Cancer - Details


( Last Updated : December 18, 2015)
Generic Name:
Ceritinib
Project Status:
Complete
Therapeutic Area:
Metastatic Non-Small Cell Lung Cancer
Manufacturer:
Novartis Pharmaceuticals Inc.
Brand Name:
Zykadia
Project Line:
Reimbursement Review
Project Number:
PC0062-000
NOC Date:

Details


Strength:
150 mg capsule
Tumour Type:
Lung
Indications:
Metastatic Non-Small Cell Lung Cancer
Funding Request:
For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib.
Review Status:
Complete
Sponsor:
Novartis Pharmaceuticals Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.